FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1976249987> ?p ?o ?g. }

• W1976249987 endingPage "968S" @default.
• W1976249987 startingPage "887S" @default.
• W1976249987 abstract "This chapter about antithrombotic therapy in neonates and children is part of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs, and Grade 2 suggests that individual patient values may lead to different choices (for a full understanding of the grading, see Guyatt et al in this supplement, pages 123S-131S). In this chapter, many recommendations are based on extrapolation of adult data, and the reader is referred to the appropriate chapters relating to guidelines for adult populations. Within this chapter, the majority of recommendations are separate for neonates and children, reflecting the significant differences in epidemiology of thrombosis and safety and efficacy of therapy in these two populations. Among the key recommendations in this chapter are the following: In children with first episode of venous thromboembolism (VTE), we recommend anticoagulant therapy with either unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) [Grade 1B]. Dosing of IV UFH should prolong the activated partial thromboplastin time (aPTT) to a range that corresponds to an anti-factor Xa assay (anti-FXa) level of 0.35 to 0.7 U/mL, whereas LMWH should achieve an anti-FXa level of 0.5 to 1.0 U/mL 4 h after an injection for twice-daily dosing. In neonates with first VTE, we suggest either anticoagulation or supportive care with radiologic monitoring and subsequent anticoagulation if extension of the thrombosis occurs during supportive care (Grade 2C). We recommend against the use of routine systemic thromboprophylaxis for children with central venous lines (Grade 1B). For children with cerebral sinovenous thrombosis (CSVT) without significant intracranial hemorrhage (ICH), we recommend anticoagulation initially with UFH, or LMWH and subsequently with LMWH or vitamin K antagonists (VKAs) for a minimum of 3 months (Grade 1B). For children with non-sickle-cell disease-related acute arterial ischemic stroke (AIS), we recommend UFH or LMWH or aspirin (1 to 5 mg/kg/d) as initial therapy until dissection and embolic causes have been excluded (Grade 1B). For neonates with a first AIS, in the absence of a documented ongoing cardioembolic source, we recommend against anticoagulation or aspirin therapy (Grade 1B). This chapter about antithrombotic therapy in neonates and children is part of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs, and Grade 2 suggests that individual patient values may lead to different choices (for a full understanding of the grading, see Guyatt et al in this supplement, pages 123S-131S). In this chapter, many recommendations are based on extrapolation of adult data, and the reader is referred to the appropriate chapters relating to guidelines for adult populations. Within this chapter, the majority of recommendations are separate for neonates and children, reflecting the significant differences in epidemiology of thrombosis and safety and efficacy of therapy in these two populations. Among the key recommendations in this chapter are the following: In children with first episode of venous thromboembolism (VTE), we recommend anticoagulant therapy with either unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) [Grade 1B]. Dosing of IV UFH should prolong the activated partial thromboplastin time (aPTT) to a range that corresponds to an anti-factor Xa assay (anti-FXa) level of 0.35 to 0.7 U/mL, whereas LMWH should achieve an anti-FXa level of 0.5 to 1.0 U/mL 4 h after an injection for twice-daily dosing. In neonates with first VTE, we suggest either anticoagulation or supportive care with radiologic monitoring and subsequent anticoagulation if extension of the thrombosis occurs during supportive care (Grade 2C). We recommend against the use of routine systemic thromboprophylaxis for children with central venous lines (Grade 1B). For children with cerebral sinovenous thrombosis (CSVT) without significant intracranial hemorrhage (ICH), we recommend anticoagulation initially with UFH, or LMWH and subsequently with LMWH or vitamin K antagonists (VKAs) for a minimum of 3 months (Grade 1B). For children with non-sickle-cell disease-related acute arterial ischemic stroke (AIS), we recommend UFH or LMWH or aspirin (1 to 5 mg/kg/d) as initial therapy until dissection and embolic causes have been excluded (Grade 1B). For neonates with a first AIS, in the absence of a documented ongoing cardioembolic source, we recommend against anticoagulation or aspirin therapy (Grade 1B)." @default.
• W1976249987 created "2016-06-24" @default.
• W1976249987 creator A5002772850 @default.
• W1976249987 creator A5046928237 @default.
• W1976249987 creator A5049630475 @default.
• W1976249987 creator A5056094943 @default.
• W1976249987 creator A5065169479 @default.
• W1976249987 creator A5070607078 @default.
• W1976249987 creator A5078007913 @default.
• W1976249987 date "2008-06-01" @default.
• W1976249987 modified "2023-09-30" @default.
• W1976249987 title "Antithrombotic Therapy in Neonates and Children" @default.
• W1976249987 cites W104552217 @default.
• W1976249987 cites W111287064 @default.
• W1976249987 cites W129971951 @default.
• W1976249987 cites W134334000 @default.
• W1976249987 cites W138791897 @default.
• W1976249987 cites W1438692237 @default.
• W1976249987 cites W145079087 @default.
• W1976249987 cites W1483107031 @default.
• W1976249987 cites W1498156640 @default.
• W1976249987 cites W150687241 @default.
• W1976249987 cites W1507068955 @default.
• W1976249987 cites W1523598805 @default.
• W1976249987 cites W1527124026 @default.
• W1976249987 cites W1543732755 @default.
• W1976249987 cites W1575111742 @default.
• W1976249987 cites W1580029011 @default.
• W1976249987 cites W162606794 @default.
• W1976249987 cites W1638042118 @default.
• W1976249987 cites W1648756109 @default.
• W1976249987 cites W178650192 @default.
• W1976249987 cites W181091954 @default.
• W1976249987 cites W1828452241 @default.
• W1976249987 cites W187302396 @default.
• W1976249987 cites W1890588548 @default.
• W1976249987 cites W1908627368 @default.
• W1976249987 cites W1909067456 @default.
• W1976249987 cites W1963752281 @default.
• W1976249987 cites W1964338019 @default.
• W1976249987 cites W1965305576 @default.
• W1976249987 cites W1965788031 @default.
• W1976249987 cites W1966167864 @default.
• W1976249987 cites W1967299542 @default.
• W1976249987 cites W1967600720 @default.
• W1976249987 cites W1968083104 @default.
• W1976249987 cites W1968152395 @default.
• W1976249987 cites W1968793410 @default.
• W1976249987 cites W1969432612 @default.
• W1976249987 cites W1969876513 @default.
• W1976249987 cites W1970149930 @default.
• W1976249987 cites W1970254926 @default.
• W1976249987 cites W1970618928 @default.
• W1976249987 cites W1970843539 @default.
• W1976249987 cites W1971074773 @default.
• W1976249987 cites W1971077963 @default.
• W1976249987 cites W1971398201 @default.
• W1976249987 cites W1971433172 @default.
• W1976249987 cites W1971801528 @default.
• W1976249987 cites W1971982302 @default.
• W1976249987 cites W1972706485 @default.
• W1976249987 cites W1972795416 @default.
• W1976249987 cites W1973717463 @default.
• W1976249987 cites W1973865042 @default.
• W1976249987 cites W1974607182 @default.
• W1976249987 cites W1975986470 @default.
• W1976249987 cites W1976197580 @default.
• W1976249987 cites W1977228067 @default.
• W1976249987 cites W1977287149 @default.
• W1976249987 cites W1977329034 @default.
• W1976249987 cites W1977491360 @default.
• W1976249987 cites W1977523526 @default.
• W1976249987 cites W1977926703 @default.
• W1976249987 cites W1978063283 @default.
• W1976249987 cites W1978963939 @default.
• W1976249987 cites W1979032722 @default.
• W1976249987 cites W1979205094 @default.
• W1976249987 cites W1979224266 @default.
• W1976249987 cites W1979456410 @default.
• W1976249987 cites W1979605409 @default.
• W1976249987 cites W1979747487 @default.
• W1976249987 cites W1980206565 @default.
• W1976249987 cites W1980563337 @default.
• W1976249987 cites W1980669153 @default.
• W1976249987 cites W1980692761 @default.
• W1976249987 cites W1980815186 @default.
• W1976249987 cites W1981047160 @default.
• W1976249987 cites W1982005636 @default.
• W1976249987 cites W1982201580 @default.
• W1976249987 cites W1982392703 @default.
• W1976249987 cites W1982972106 @default.
• W1976249987 cites W1983180253 @default.
• W1976249987 cites W1983802649 @default.
• W1976249987 cites W1984248533 @default.
• W1976249987 cites W1984349062 @default.
• W1976249987 cites W1984833612 @default.
• W1976249987 cites W1985305121 @default.
• W1976249987 cites W1985441587 @default.

• next